Artal Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Artal Group’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,133,775	Closed	-$884K	–	97
2023 Q3	$884K	Hold	1,133,775	–	–	0.04%	79
2023 Q2	$1.05M	Buy	+1,133,775	New	+$1.35M	0.03%	92
2018 Q1	–	Sell	-700,000	Closed	-$4.68M	–	110
2017 Q4	$4.68M	Buy	700,000 +200,000	+40%	+$1.54M	0.07%	73
2017 Q3	$4.09M	Buy	500,000 +200,000	+67%	+$1.25M	0.07%	70
2017 Q2	$1.35M	Hold	300,000	–	–	0.02%	101
2017 Q1	$1.65M	Hold	300,000	–	–	0.04%	84
2016 Q4	$1.22M	Buy	300,000 +100,000	+50%	+$480K	0.03%	84
2016 Q3	$1.41M	Buy	+200,000	New	+$1.53M	0.03%	88

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Artal Group's ADAP Position: Q4 2023 in Review

Artal Group sold out of Adaptimmune Therapeutics (ADAP) in Q4 2023, closing a stake of 1,133,775 shares — an estimated $884K sold.

Artal Group first reported a position in ADAP in Q3 2016 and held it in 8 quarters. The position peaked at $4.68M in Q4 2017. 79 funds tracked by Wall St. Rank hold ADAP as of Q4 2023.

Artal Group reported no remaining Adaptimmune Therapeutics position as of Q4 2023 after selling out during the quarter.
Artal Group sold 1,133,775 Adaptimmune Therapeutics shares in Q4 2023, an estimated $884K.
Artal Group first reported a position in Adaptimmune Therapeutics in Q3 2016 and held it in 8 quarters.
Artal Group's Adaptimmune Therapeutics position peaked at $4.68M in Q4 2017.
79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2023.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.